15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering PTC Therapeutics Inc, 8 rate it Buy or better, 1 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets range widely, $50.00 to $130.00 (about 2.6x), a sign of real disagreement on valuation. The average target of $97.60 sits 42% above the current $68.82. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.25 next quarter toward $2.50 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Moderate Buy
Strong Buy00%
Buy880%
Hold110%
Sell110%
Strong Sell00%
Based on 10 analysts giving stock ratings to PTC Therapeutics Inc.
As of Sep, 8 of 10 firms rate PTCT a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
PTCT EPS & revenue forecast
EPS · NEXT QUARTER
$0.25
Range $0.09 – $0.50 · 3 analysts · -114% YoY
Next period, 3 analysts expect PTC Therapeutics Inc to earn $0.25 a share (range $0.09 – $0.50), versus $-1.80 a year earlier. Full-year consensus is $1.60, growing to $2.50 the year after.
REVENUE · NEXT QUARTER
$319.6M
Range $286.8M – $352.3M · 3 analysts · +94% YoY
Revenue is expected to reach $319.6M (range $286.8M – $352.3M), +94.1% year-over-year. Full-year consensus is $1.3B, rising to $1.4B next year.
Top analysts covering PTC Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PTCT.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #3
Buy
$104.00+51.1% to target
Overall win rate
64%
+ Follow
#2
Joel Beatty
Baird · Rank #80
Buy
$70.00+1.7% to target
Overall win rate
48%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #169
Buy
$130.00+88.9% to target
Overall win rate
38%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #317
Buy
$96.00+39.5% to target
Overall win rate
47%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #371
Hold
$85.00+23.5% to target
Overall win rate
28%
+ Follow
PTCT stock forecast FAQ
What is PTCT's average 12-month price target?+
The 10 analysts with a live target average $97.60 for PTC Therapeutics Inc over the next 12 months, ranging from a $130.00 high to a $50.00 low.
Is PTCT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 10 analyst ratings, 8 are Buy or Strong Buy, 1 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for PTCT?+
The Street-high target is $130.00 (Cantor Fitzgerald), and the Street-low is $50.00 (Goldman Sachs). The average of all 10 active targets is $97.60.
How many Wall Street analysts cover PTCT?+
10 analysts have an active rating on PTC Therapeutics Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering PTCT?+
Among analysts who currently cover PTCT, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #3). Their current call is Buy with a $104.00 target.
What is PTC Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $0.25 per share (range $0.09 – $0.50) across 3 analysts. Full-year EPS is projected at $1.60, rising to $2.50 the following year.
How much revenue is PTC Therapeutics Inc expected to report next quarter?+
Consensus revenue is $319.6M (range $286.8M – $352.3M). Full-year revenue is projected at $1.3B, growing to $1.4B next year.
Have analysts been upgrading or downgrading PTCT lately?+
As of Sep, 8 of 10 firms rate PTCT a Buy (1 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PTCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
